Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

MONISTAT 7 DUAL-PAK 100 MG

MICONAZOLE NITRATE : 100 MG MICONAZOLE NITRATE : 2 % · DIN 02126257 · INSIGHT PHARMACEUTICALS, LLC

Health Canada status: MARKETED

What is MONISTAT 7 DUAL-PAK?

MONISTAT 7 DUAL-PAK 100 MG contains MICONAZOLE NITRATE : 100 MG MICONAZOLE NITRATE : 2 %. It is listed in the Health Canada Drug Product Database under DIN 02126257, held by INSIGHT PHARMACEUTICALS, LLC, supplied as CREAM ; SUPPOSITORY for TOPICAL ; VAGINAL administration. Health Canada currently lists it as marketed, status dated 11-Dec-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is MONISTAT 7 DUAL-PAK used for?

Local treatment of vulvovaginal candidiasis (moniliasis) and relief of associated external itching and irritation.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02126257
Brand nameMONISTAT 7 DUAL-PAK
Generic / active ingredientMICONAZOLE NITRATE : 100 MG MICONAZOLE NITRATE : 2 %
ManufacturerINSIGHT PHARMACEUTICALS, LLC
Strength100 MG
Dosage formCREAM ; SUPPOSITORY
Route of administrationTOPICAL ; VAGINAL
ScheduleNON-PRESCRIPTION DRUGS
ATC codeG01AF04 MICONAZOLE
AHFS class84:04.08.08
BiosimilarNo
Health Canada statusMARKETED
Status date11-Dec-2012
Original market date1994-12-31 00:00:00

How is it administered?

Cream: 5g daily for 7 days. Ovule: 400mg daily for 3 days. Dual-Paks: Intravaginal treatment plus external cream applied twice daily for up to 7 days. Administer at bedtime.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at controlled room temperature (15°C - 30°C).

How is it supplied?

Cream: 7 prefilled applicators. Ovules: 3 ovules with applicators. Dual-Paks: Suppositories (7) or Ovules (3) plus a 9g tube of 2% cream.

Contraindications

Known hypersensitivity to this drug or any of its ingredients.

Warnings and precautions

Discontinue if sensitization/irritation occurs. Reduces effectiveness of latex condoms/diaphragms. Consult doctor if first-time infection, fever, or abdominal pain occurs.

What can be used instead?

Other Canadian products sharing ATC code G01AF04 MICONAZOLE. 6 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
MICONAZOLE 3 DAY OVULE TREATMENT 400MG400 MGSUPPOSITORYVITA HEALTH PRODUCTS INCMARKETEDDIN 02171775
MICONAZOLE NITRATE VAGINAL CREAM 2%2 %CREAMVITA HEALTH PRODUCTS INCMARKETEDDIN 02245546
MICONAZOLE NITRATE VAGINAL CREAM USP, 2%2 %CREAMTARO PHARMACEUTICALS INCMARKETEDDIN 02231533
MONISTAT 3 VAGINAL CREAM4 %CREAMINSIGHT PHARMACEUTICALS, LLCMARKETEDDIN 02244005
MONISTAT 7 VAGINAL CREAM2 %CREAMINSIGHT PHARMACEUTICALS, LLCMARKETEDDIN 02084309
MICONAZOLE 7 - CRM VAG 2%2 %CREAMTECHNILAB PHARMA INC.CANCELLED POST MARKETDIN 02194368
MICOZOLE2 %CREAMTARO PHARMACEUTICALS INCCANCELLED POST MARKETDIN 02231106
MONAZOLE 7 - CRM 20MG/G20 MGCREAMTECHNILAB PHARMA INC.CANCELLED POST MARKETDIN 02219476
MONISTAT 1 COMBINATION PACK2 %CREAM ; SUPPOSITORYINSIGHT PHARMACEUTICALS, LLCDORMANTDIN 02239600
MONISTAT 1 VAGINAL OVULE1200 MGSUPPOSITORYINSIGHT PHARMACEUTICALS, LLCDORMANTDIN 02239601

Who else supplies MICONAZOLE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. MICONAZOLE appears in 785 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for MONISTAT 7 DUAL-PAK

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for MONISTAT 7 DUAL-PAK

Health Canada Drug Product Database (DPD), DIN 02126257. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.